EntryPoint Capital LLC Buys Shares of 197 Atrion Co. (NASDAQ:ATRI)

EntryPoint Capital LLC bought a new stake in shares of Atrion Co. (NASDAQ:ATRI) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 197 shares of the medical instruments supplier’s stock, valued at approximately $91,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Copeland Capital Management LLC raised its stake in Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 31 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in Atrion during the 4th quarter valued at $36,000. Harbor Investment Advisory LLC raised its stake in Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 47 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Atrion by 592.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Atrion during the 4th quarter valued at $108,000. Institutional investors own 66.19% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Atrion in a research note on Thursday. They issued a “sell” rating on the stock.

Atrion Price Performance

Shares of ATRI traded up $0.22 during midday trading on Friday, reaching $457.87. The stock had a trading volume of 4,138 shares, compared to its average volume of 23,310. The firm’s 50 day moving average price is $456.35 and its 200-day moving average price is $413.63. The company has a market capitalization of $805.85 million, a P/E ratio of 43.01 and a beta of 0.68. Atrion Co. has a 52 week low of $274.98 and a 52 week high of $575.88.

Atrion (NASDAQ:ATRI) last announced its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. The company had revenue of $47.33 million for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Atrion Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were given a dividend of $2.20 per share. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date was Friday, June 14th. Atrion’s dividend payout ratio (DPR) is presently 82.71%.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.